Lee SM, Schulz C, Prabhash K, Kowalski D, et al. First-line atezolizumab monotherapy versus single-agent chemotherapy in patients with non-small-cell lung cancer ineligible for treatment with a platinum-containing regimen (IPSOS): a phase 3, global, multicentre, open-label, randomised controlled stu Lancet 2023 Jul 6:S0140-6736(23)00774-2. doi: 10.1016/S0140-6736(23)00774.
PMID: 37423228